When considering the performance of the pharmaceuticals sector, an investor is almost always challenged with the question of definitions. Simply put, what exactly is a pharmaceutical company and where are the lines between "biotech," "specialty pharmaceutical," "generic," and regular ol' pharmaceutical companies? (For related reading, see Evaluating Pharmaceutical Companies.)
Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Leaving aside the issue of nomenclature, and acknowledging that there is some subjectivity involved in who is included or left out, this was actually a fairly strong year for the sector. True, fewer people are seeing the doctor, high unemployment means fewer people on insurance rolls, and overall health care spending has not been very strong. Nevertheless, the market has warmed to these stocks, as the iShares Dow Jones U.S. Pharmaceuticals ETF (ARCA:IHE) has handily beaten the market this year and risen by a solid mid-teens percentage.

Relatively Little Red
One of the first things that jumps about this sector's 2011 performance is the relatively small number of losers. Forest Labs (NYSE:FRX) and Novartis (NYSE:NVS) both seem likely to end the year in the red, with Forest Labs really suffering from Wall Street's doubts regarding the company's ability to replace soon-to-be-lost sales from patent expirations. Warner Chilcott (Nasdaq:WCRX) has done even worse, though, with the stock returning a loss of more than 30%, as the company lost exclusivity on osteoporosis drug Actonel, saw a dermatology drug distribution agreement end, and faced higher than expected costs in converting a manufacturing plant into a distribution center.

Some Big Winners
On the green side of the fence, there were some surprisingly successful stories in the drug sector this year. Valeant Pharmaceuticals (NYSE:VRX) has been aggressive in restructuring its operations and the stock has returned nearly 60% so far this year. Even the goliaths have gotten into the act; Bristol-Myers Squibb (NYSE:BMY) and GlaxoSmithKline (NYSE:GSK) have risen over 30 and 20% respectively, this year.

Bristol-Myers not only has an encouraging pipeline, but the company has delivered better-than-expected sales of some key new drugs, while also paying an attractive dividend. Glaxo, meanwhile, has coupled good emerging markets and vaccine exposure, and has perhaps benefited from being too badly beaten-down in times past.

Are the Gain Already Bagged?
The downside to this strong 2011 performance may be that it has robbed some of the momentum from 2012. Many stocks have already traded up on the expected benefits of new product approvals and further cost-cutting, leaving many companies hard pressed to deliver more red meat to an always growth-hungry market.

The Bottom Line
Looking into the next year, then, investors may be better served shopping in the scratch-and-dent aisles. Forest Labs, for instance, has a long history of defying the skeptics and finding ways of rebuilding its revenue. Novartis has a well-integrated suite of businesses and an undemanding valuation, while Merck (NYSE:MRK) may be undervalued for its earnings quality. If there is a 2011 winner to bet on for 2012, it may well be Pfizer (NYSE:PFE). Though this stock has climbed nicely already (up more than 20% for 2011), the stock still looks undervalued for its long-term potential. (For a quick introduction to biotechnology's place in the market, read A Primer On The Biotech Sector.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    3 Resilient Oil Stocks for a Down Market

    Stuck on oil? Take a look at these six stocks—three that present risk vs. three that offer some resiliency.
  2. Economics

    Keep an Eye on These Emerging Economies

    Emerging markets have been hammered lately, but these three countries (and their large and young populations) are worth monitoring.
  3. Stock Analysis

    Is Pepsi (PEP) Still a Safe Bet?

    PepsiCo has long been known as one of the most resilient stocks throughout the broader market. Is this still the case today?
  4. Investing

    The ABCs of Bond ETF Distributions

    How do bond exchange traded fund (ETF) distributions work? It’s a question I get a lot. First, let’s explain what we mean by distributions.
  5. Stock Analysis

    The 5 Best Dividend Stocks in the Healthcare Sector

    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash flows to afford high payouts.
  6. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  7. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  8. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  9. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  10. Stock Analysis

    An Auto Stock Alternative to Ford and GM

    If you're not sure where Ford and General Motors are going, you might want to look at this auto investment option instead.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!